Table 1 Baseline characteristics.
From: Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
Characteristic | ASXL1 mutation (N = 10) | P | Other non-ABL1 mutation (N = 13) | P | No mutation (N = 48) |
|---|---|---|---|---|---|
Age, median (range) | 62 (27–73) | 0.7 | 60 (25–80) | 0.9 | 59 (18–77) |
Female, no. (%) | 5 (50%) | 0.9 | 5 (43%) | 0.9 | 22 (46%) |
WBC, median × 109 (range) | 42.7 (3–281) | 0.2 | 30 (3–341) | 0.4 | 84.8 (3–538) |
Hb, median g/dL (range) | 10.2 (8.0–13.9) | 0.2 | 11.6 (7.5–15.5) | 0.9 | 12.0 (6.7–16.3) |
Platelets, median × 109 (range) | 405 (137–1265) | 0.4 | 193 (74–375) | 0.02 | 333 (19–1832) |
Basophils, median% (range) | 2 (0–5) | 0.8 | 1 (0–4) | 0.03 | 2 (0–5) |
BM Blasts, median% (range) | 2 (0–5) | 0.6 | 1 (0–6) | 0.9 | 2 (0–5) |
ABL1 mutation, no./tested (%) | 2/7 (29%) | 0.3 | 1/9 (11%) | 0.9 | 2/18 (11%) |
Sokal Score, no./tested (%) | 0.5 | 0.3 | |||
Low | 1/8 (12%) | 3/10 (30%) | 9/39 (23%) | ||
Intermediate | 4/8 (50%) | 7/10 (70%) | 23/39 (59%) | ||
High | 3/8 (38%) | 0/10 (0%) | 7/39 (18%) | ||
1st Line Therapy | 0.5 | 0.2 | |||
Imatinib | 2 (20%) | 4 (31%) | 8 (17%) | ||
Dasatinib | 7 (70%) | 3 (23%) | 27 (56%) | ||
Other | 1 (10%) | 6 (46%) | 13 (27%) | ||
HSCT | 2 (20%) | 0.02 | 1 (8%) | 0.3 | 1 (2%) |
